The global pharmaceutical industry is undergoing profound transformation. As multiple blockbuster drug patents expire successively and the United States continues to advance its drug pricing reform, industry leaders are compelled to accelerate strategic adjustments. Against this backdrop, AbbVie (ABBV) and Pfizer (PFE), as two closely watched pharmaceutical giants, present distinctly different development trajectories and risk-return profiles, making them core candidates for investors weighing their healthcare sector allocations.
AbbVie has successfully reduced its dependence on Humira, the former “king of drugs.” Its latest annual report shows that the company is focusing on high-growth areas such as immunology, neuroscience, and medical aesthetics. In fiscal year 2025, the two core immunology drugs, Skyrizi and Rinvoq, together contributed nearly 42% of revenue, driving full-year total revenue to approximately $61.2 billion, an increase of about 9% year-over-year. Although net profit declined slightly year-over-year to approximately $4.2 billion, the company demonstrated its ability to maintain revenue growth even as mature products face competitive pressures. On the financial side, as of December 2025, its free cash flow stood at approximately $17.8 billion, but its debt-to-equity ratio was -21.1 times, and its current ratio was only 0.7 times, indicating relatively high financial leverage and short-term debt repayment pressure.
Pfizer, for its part, has been committed to deploying the substantial cash accumulated during the pandemic into the research, development, and acquisition of new therapies for oncology and obesity. Its fiscal year 2025 revenue came in at approximately $62.6 billion, a slight decline of 1.6% year-over-year, reflecting the normalization of demand for COVID-19 products. However, net profit rebounded significantly to approximately $7.8 billion, a marked improvement from two years earlier. Its balance sheet is more robust, with a debt-to-equity ratio of approximately 0.8 times and a current ratio of 1.2 times. Free cash flow of about $9.1 billion provides solid support for dividend payments and internal R&D. Currently, the anticoagulant drug Eliquis accounts for about 13% of its total revenue, and the company is actively expanding its oncology pipeline through acquisitions such as that of Seagen.
Both companies face significant patent expiration pressures. AbbVie, under the influence of the Inflation Reduction Act, may see government pricing interventions on its high-priced drugs such as Botox and Vraylar, while its complex international supply chain also introduces operational uncertainties. Pfizer, meanwhile, will encounter a “patent cliff” between 2026 and 2030 and is entangled in multiple product liability and patent litigation disputes. The successful clinical translation of its R&D pipeline will be critical to its future performance.
From a valuation perspective, Pfizer’s forward price-to-earnings ratio and price-to-sales ratio are both lower than AbbVie’s, making it more value-oriented. AbbVie, on the other hand, recently announced its acquisition of Apogee Therapeutics (APGE), aiming to drive growth through external M&A. The market expects its net profit to surge to $14.6 billion in 2026, with revenue increasing to $67.2 billion. Some Wall Street analysts are optimistic about its pipeline candidates for schizophrenia, Parkinson’s disease, and other indications. For Pfizer, net profit is projected to grow by about 40% to over $11 billion in 2026, though revenue is expected to increase only slightly to $61.7 billion, with potential headwinds from patent expirations in subsequent years. Nevertheless, the company’s small-molecule oral GLP-1 drug developed in collaboration with a Chinese pharmaceutical partner, along with three upcoming FDA decision dates, offer hope for its future product launches.
